Mindfulness training reduces dropout rates and relapses in opioid addiction treatment

Supplementing standard opioid addiction treatment with Mindfulness Oriented Recovery Enhancement (MORE) -; an intervention that incorporates mindfulness training, savoring skills, and cognitive reappraisal -; cuts program dropout rates by 59 percent and relapses by 42 percent, according to Rutgers-led research.

These trial results come from Rutgers Health amid unprecedented opioid abuse. An estimated 10 million Americans misuse opioids or have opioid use disorder, while annual overdose deaths have exceeded 80,000.

Treatment with methadone or buprenorphine – alone or in combination with cognitive behavioral therapy – is imperfect. Half of all people drop out of treatment within a year, and half of all people who continue treatment keep using opioids.

"Better treatment protocols could save thousands of lives per year, and the data we have from our pilot study and this phase II trial suggest mindfulness training may create a genuinely better treatment protocol," said Nina Cooperman, an associate professor of psychiatry at Rutgers Robert Wood Johnson Medical School and first author of the study published in JAMA Psychiatry.

Mindfulness training teaches people to focus on the present moment, without judgment, and on sensory inputs such as the feeling of breathing in and out. Previous studies demonstrating that such training can prevent addiction to opioid pain medication led Cooperman's team to ask whether similar techniques could help people who already have an opioid use disorder.

A small pilot study found that mindfulness training combined with methadone treatment produced good outcomes. The pilot's success paved the way for this larger study, which, in turn, has justified two large-scale studies that could change standards of care.

The current trial provided eight two-hour sessions to 77 of 154 patients in methadone treatment for opioid use disorder.

"Opioid use disorder changes your brain so that opioid use becomes the only thing that feels rewarding. MORE helps people retrain themselves to find healthy experiences rewarding again by focusing mindfully on the taste of a meal, the beauty of a landscape or the smell of a flower," said Cooperman, who added the program literally includes observing and smelling roses during sessions.

Mindfulness training also gives people another tool for handling cravings.

Cognitive behavioral therapy, which is common in treatment programs, teaches people to reframe their thoughts and distract themselves from cravings. Mindfulness training teaches them to stay present with the craving and notice that they pass. Both strategies can work, so both are valuable."

Nina Cooperman, associate professor of psychiatry, Rutgers Robert Wood Johnson Medical School

The success of mindfulness training in Cooperman's study may stem from its ability to help patients manage pain. Most patients began the study with significant chronic pain -; and, thus, a strong incentive to use pain-killing opioids -; but patients who received MORE reported a 10 percent reduction in pain over the 16 weeks of the study.

Looking forward, Cooperman and her team are working on larger studies, which are designed to provide further evidence for the efficacy of MORE and to optimize protocols for use in the real world.

"We still have lots of open questions. How can we train clinicians to implement MORE in treatment programs? What is the best structure for implementing MORE-;in-person or virtual? Our current research is working to answer some of these questions," Cooperman said. "The findings from this study suggest MORE really can improve outcomes for a lot of people in substance abuse treatment."

Source:
Journal reference:

Cooperman, N. A., et al. (2023). Telehealth Mindfulness-Oriented Recovery Enhancement vs Usual Care in Individuals With Opioid Use Disorder and Pain: A Randomized Clinical Trial. JAMA Psychiatry. doi.org/10.1001/jamapsychiatry.2023.5138.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Δ-8-Tetrahydrocannabinol use among US teens climbs in states without regulation